FIG 2.

Antitumor activity of vebreltinib as assessed by blinded independent review committee. (A) Treatment exposure and response duration of patients. (B) The best percentage changes from baseline in target lesions of patients against MET exon 14 (METex14) splice site variants, alteration types, and MET amplification. Indels are insertion or deletion mutations. A durable responder is defined as a subject with a confirmed response lasting at least 183 days (6 months). (C) Subgroup analysis of ORR assessed by blinded independent review committee. ECOG PS, Eastern Cooperative Oncology Group performance status; METex14, MET exon 14; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.